#nmCSPC - Twitter Hashtag

Prostate Cancer and Prostatic Diseases @pcan_journal

almost 2 years ago

🚨 New Study Alert! 🚨 Exploring the role of PSA doubling time (PSADT) in #ProstateCancer management: 📊 In a contemporary cohort of Veterans Health Administration patients with nonmetastatic castration-sensitive prostate cancer (#nmCSPC), rapid PSADT (≤9 months) was linked to: - Shorter time to therapy - Increased risk of metastasis Lower metastasis-free & overall survival 🏥 Early secondary treatment showed better outcomes compared to historical data on delayed treatment. Is this due to the timing of therapy or overall advances in cancer care? More research needed! @SFreedlandMD More on: https://t.co/hi8bXy7cAZ

pcan_journal's tweet photo. 🚨 New Study Alert! 🚨
Exploring the role of PSA doubling time (PSADT) in #ProstateCancer management:
📊 In a contemporary cohort of Veterans Health Administration patients with nonmetastatic castration-sensitive prostate cancer (#nmCSPC), rapid PSADT (≤9 months) was linked to:
- Shorter time to therapy
- Increased risk of metastasis
Lower metastasis-free & overall survival
🏥 Early secondary treatment showed better outcomes compared to historical data on delayed treatment. Is this due to the timing of therapy or overall advances in cancer care? More research needed! @SFreedlandMD
More on: https://t.co/hi8bXy7cAZ

0

8

2

1

2K

CancerTherapyAdvisor @CancerTherAdvsr

over 2 years ago

The @US_FDA has approved the supplemental new drug application for Xtandi (enzalutamide) for the treatment of patients with nonmetastatic castration-sensitive #prostatecancer and biochemical recurrence at high risk for metastasis. From @eMPR. https://t.co/TYPgaWwVhJ #nmCSPC

0

2

1

0

263

がんナビ通信 @cancer_navi

over 2 years ago

経口アンドロゲン受容体阻害薬 #エンザルタミドについて、生化学的再発のリスクが高い #非転移性去勢感受性前立腺がん（#nmCSPC、#nmHSPC）への適応拡大が米国で承認されました。 https://t.co/rXafTLL96A

0

2

0

527

Targeted Oncology @TargetedOnc

over 2 years ago

BREAKING: The #FDA has approved enzalutamide for patients with nonmetastatic castration-sensitive prostate cancer with high-risk biochemical recurrence. #pcsm #nmCSPC https://t.co/XohfM3I46k

TargetedOnc's tweet photo. BREAKING: The #FDA has approved enzalutamide for patients with nonmetastatic castration-sensitive prostate cancer with high-risk biochemical recurrence. #pcsm #nmCSPC

https://t.co/XohfM3I46k https://t.co/i0iYGwuFwZ

0

2

1

0

538

UroToday.com

@urotoday

almost 3 years ago

Exciting news! @FDA grants Priority Review for #XTANDI in #nmCSPC with high-risk biochemical recurrence. If approved, #XTANDI could be the first novel hormone therapy for this earlier stage. #ReadNow details on UroToday > https://t.co/uxrg0aTcBt @pfizer @AstellasUS #EMBARK

urotoday's tweet photo. Exciting news! @FDA grants Priority Review for #XTANDI in #nmCSPC with high-risk biochemical recurrence. If approved, #XTANDI could be the first novel hormone therapy for this earlier stage. #ReadNow details on UroToday > https://t.co/uxrg0aTcBt @pfizer @AstellasUS #EMBARK https://t.co/ynCSLYeIw4

0

4

1

985

Targeted Oncology @TargetedOnc

about 3 years ago

Patients with #nmCSPC who received #enzalutamide + #leuprolide had a lower risk of metastasis or death vs those who did not receive enzalutamide. @GenesisCare | #pcsm https://t.co/Rcz99y3FYX

0

2

1

0

623

Top Tweets for #nmCSPC

Last Seen Hashtags on Sotwe

Trends for you

Most Popular Users